Compare Stocks: VCYT, TWST, EXEL, and ARWR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$85.83 -1.2%	$79.77	$15.01 ▼ $95.49	$12.24B	1.27	2.30 million shs	1.05 million shs
EXEL Exelixis	$52.20 -7.9%	$54.10	$33.76 ▼ $57.57	$14.25B	0.44	2.48 million shs	5.41 million shs
TWST Twist Bioscience	$108.99 -5.2%	$88.31	$23.30 ▼ $115.56	$7.21B	2.14	1.45 million shs	1.83 million shs
VCYT Veracyte	$46.15	$53.76	$25.52 ▼ $60.91	$3.71B	1.95	1.34 million shs	939,826 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	-1.24%	-1.71%	-1.31%	+18.07%	+426.24%
EXEL Exelixis	-7.94%	-6.74%	-8.55%	+8.39%	+38.42%
TWST Twist Bioscience	-5.23%	+19.34%	+19.73%	+91.72%	+320.81%
VCYT Veracyte	0.00%	-22.80%	-17.82%	+14.18%	+92.53%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$85.83 -1.2%	$79.77	$15.01 ▼ $95.49	$12.24B	1.27	2.30 million shs	1.05 million shs
EXEL Exelixis	$52.20 -7.9%	$54.10	$33.76 ▼ $57.57	$14.25B	0.44	2.48 million shs	5.41 million shs
TWST Twist Bioscience	$108.99 -5.2%	$88.31	$23.30 ▼ $115.56	$7.21B	2.14	1.45 million shs	1.83 million shs
VCYT Veracyte	$46.15	$53.76	$25.52 ▼ $60.91	$3.71B	1.95	1.34 million shs	939,826 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	-1.24%	-1.71%	-1.31%	+18.07%	+426.24%
EXEL Exelixis	-7.94%	-6.74%	-8.55%	+8.39%	+38.42%
TWST Twist Bioscience	-5.23%	+19.34%	+19.73%	+91.72%	+320.81%
VCYT Veracyte	0.00%	-22.80%	-17.82%	+14.18%	+92.53%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	2.62	Moderate Buy	$97.33	13.40% Upside
EXEL Exelixis	2.26	Hold	$49.79	-4.63% Downside
TWST Twist Bioscience	2.70	Moderate Buy	$98.30	-9.81% Downside
VCYT Veracyte	2.64	Moderate Buy	$54.33	17.73% Upside

Current Analyst Ratings Breakdown

Latest VCYT, TWST, EXEL, and ARWR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/6/2026	EXEL Exelixis	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Hold	$56.00 ➝ $52.00
8/6/2026	ARWR Arrowhead Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$115.00 ➝ $120.00
8/6/2026	EXEL Exelixis	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$52.00
8/6/2026	EXEL Exelixis	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$47.00 ➝ $51.00
8/5/2026	TWST Twist Bioscience	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$85.00 ➝ $115.00
8/4/2026	VCYT Veracyte	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$66.00 ➝ $54.00
8/4/2026	TWST Twist Bioscience	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$113.00 ➝ $115.00
8/4/2026	VCYT Veracyte	Stephens Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$68.00 ➝ $55.00
8/4/2026	VCYT Veracyte	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Underweight	$47.00 ➝ $44.00
8/3/2026	TWST Twist Bioscience	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/3/2026	VCYT Veracyte	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Hold	$60.00 ➝ $50.00

(Data available from 8/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$669.50M	18.06	$0.12 per share	727.89	$3.31 per share	25.93
EXEL Exelixis	$2.32B	5.66	$2.79 per share	18.73	$8.06 per share	6.48
TWST Twist Bioscience	$376.57M	18.15	N/A	N/A	$7.11 per share	15.33
VCYT Veracyte	$517.15M	7.17	$1.49 per share	30.98	$17.27 per share	2.67

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$1.63M	-$2.25	N/A	N/A	N/A	-47.79%	-60.06%	-17.37%	N/A
EXEL Exelixis	$782.57M	$3.01	16.42	14.11	1.64	35.33%	40.94%	31.01%	N/A
TWST Twist Bioscience	-$77.67M	-$2.22	N/A	N/A	N/A	-31.66%	-28.64%	-19.94%	N/A
VCYT Veracyte	$66.35M	$1.41	32.73	33.20	N/A	20.37%	9.26%	8.61%	N/A

Latest VCYT, TWST, EXEL, and ARWR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2026	Q2 2026	EXEL Exelixis	$0.8530	$0.91	+$0.0570	$0.8438	$636.40 million	$628.69 million
8/4/2026	Q3 2026	ARWR Arrowhead Pharmaceuticals	-$1.23	-$1.36	-$0.13	-$1.36	$44.17 million	$75.25 million
8/3/2026	Q3 2026	TWST Twist Bioscience	-$0.5063	-$0.56	-$0.0538	-$0.56	$114.55 million	$118.38 million
7/30/2026	Q2 2026	VCYT Veracyte	$0.4103	$0.54	+$0.1297	$0.31	$144.59 million	$150.32 million
5/7/2026	Q2 2026	ARWR Arrowhead Pharmaceuticals	-$1.0950	-$0.93	+$0.1650	-$0.93	$73.84 million	$73.74 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
EXEL Exelixis	N/A	N/A	N/A	N/A	N/A
TWST Twist Bioscience	N/A	N/A	N/A	N/A	N/A
VCYT Veracyte	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	1.77	5.90	6.23
EXEL Exelixis	N/A	3.26	3.19
TWST Twist Bioscience	0.03	2.67	2.42
VCYT Veracyte	N/A	9.16	8.80

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
EXEL Exelixis	85.27%
TWST Twist Bioscience	N/A
VCYT Veracyte	N/A

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	3.60%
EXEL Exelixis	2.60%
TWST Twist Bioscience	3.08%
VCYT Veracyte	1.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	140.86 million	135.79 million	Optionable
EXEL Exelixis	1,077	251.35 million	244.82 million	Optionable
TWST Twist Bioscience	990	62.71 million	60.78 million	Optionable
VCYT Veracyte	790	80.39 million	79.11 million	Optionable

VCYT, TWST, EXEL, and ARWR Headlines

Recent News About These Companies

Royal Bank of Canada Grows Stock Holdings in Veracyte, Inc. $VCYT

33 minutes ago | marketbeat.com

Veracyte, Inc. $VCYT Shares Sold by Janus Henderson Group PLC

40 minutes ago | marketbeat.com

Veracyte (NASDAQ:VCYT) Growth Story Gains Fresh Market Attention

August 6 at 11:57 PM | kalkinemedia.comK

Empowered Funds LLC Buys 68,171 Shares of Veracyte, Inc. $VCYT

August 6 at 3:36 AM | marketbeat.com

Morgan Stanley Has Lowered Expectations for Veracyte (NASDAQ:VCYT) Stock Price

August 6 at 2:36 AM | americanbankingnews.com

Renaissance Technologies LLC Takes Position in Veracyte, Inc. $VCYT

August 5 at 4:47 AM | marketbeat.com

Guggenheim Reaffirms Their Buy Rating on Veracyte (VCYT)

August 4 at 1:06 PM | theglobeandmail.com

Stephens Issues Pessimistic Forecast for Veracyte (NASDAQ:VCYT) Stock Price

August 4 at 9:29 AM | marketbeat.com

Veracyte (NASDAQ:VCYT) Price Target Cut to $44.00 by Analysts at Morgan Stanley

August 4 at 9:11 AM | marketbeat.com

Arrowstreet Capital Limited Partnership Takes Position in Veracyte, Inc. $VCYT

August 4 at 3:04 AM | marketbeat.com

Critical Contrast: Intuitive Surgical (NASDAQ:ISRG) & Veracyte (NASDAQ:VCYT)

August 1, 2026 | americanbankingnews.com

Veracyte Q2 Earnings Call Highlights

July 31, 2026 | marketbeat.com

Veracyte (NASDAQ:VCYT) Posts Quarterly Earnings Results, Beats Estimates By $0.10 EPS

July 31, 2026 | marketbeat.com

Veracyte (NASDAQ:VCYT) Shares Gap Down - Here's What Happened

July 31, 2026 | marketbeat.com

Is Veracyte (VCYT) Fully Valued After Raising 2026 Revenue Guidance?

July 31, 2026 | finance.yahoo.com

Veracyte Q2 Non-GAAP Earnings, Revenue Rise; 2026 Revenue Guidance Raised

July 31, 2026 | finance.yahoo.com

Veracyte, Inc. 2026 Q2 - Results - Earnings Call Presentation

July 31, 2026 | seekingalpha.com

Sei Investments Co. Has $13.53 Million Stock Holdings in Veracyte, Inc. $VCYT

July 31, 2026 | marketbeat.com

Veracyte, Inc. (VCYT) Q2 2026 Earnings Call Transcript

July 31, 2026 | seekingalpha.com

Veracyte: Q2 Earnings Snapshot

July 30, 2026 | stamfordadvocate.comS

Veracyte (VCYT) Q2 2026 Earnings

July 30, 2026 | 247wallst.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCYT, TWST, EXEL, and ARWR Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$85.83 -1.08 (-1.24%)

Closing price 08/6/2026 04:00 PM Eastern

Extended Trading

$85.95 +0.12 (+0.14%)

As of 05:20 AM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Exelixis NASDAQ:EXEL

$52.20 -4.50 (-7.94%)

Closing price 08/6/2026 04:00 PM Eastern

Extended Trading

$52.12 -0.08 (-0.14%)

As of 04:39 AM Eastern

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Twist Bioscience NASDAQ:TWST

$108.99 -6.02 (-5.23%)

Closing price 08/6/2026 04:00 PM Eastern

Extended Trading

$112.06 +3.07 (+2.82%)

As of 05:26 AM Eastern

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Veracyte NASDAQ:VCYT

$46.15 0.00 (0.00%)

Closing price 08/6/2026 04:00 PM Eastern

Extended Trading

$46.33 +0.18 (+0.40%)

As of 04:23 AM Eastern

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VCYT, TWST, EXEL, and ARWR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VCYT, TWST, EXEL, and ARWR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VCYT, TWST, EXEL, and ARWR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCYT, TWST, EXEL, and ARWR Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

Exelixis NASDAQ:EXEL

Twist Bioscience NASDAQ:TWST

Veracyte NASDAQ:VCYT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VCYT, TWST, EXEL, and ARWR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VCYT, TWST, EXEL, and ARWR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VCYT, TWST, EXEL, and ARWR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCYT, TWST, EXEL, and ARWR Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

Exelixis NASDAQ:EXEL

Twist Bioscience NASDAQ:TWST

Veracyte NASDAQ:VCYT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools